Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2013

View Archived Issues

LY-2405319 as a potential new treatment for metabolic disorders

Novel, cost-effective nanoparticle technology for male contraception

Researchers from Roche present a new clinical candidate for schizophrenia

Results of phase I trial of AZD-8330 in patients with advanced malignancies reported

Spanish team patents new agents for gastrointestinal ulcer

F2G and the University of Manchester to develop new antifungal agents

Karo Bio extends collaboration with Pfizer

Kiadis Pharma gains innovation credit from Dutch government

Preliminary data presented from clinical trials of new drugs for the treatment of tinnitus

Sandoz begins phase III trial of biosimilar etanercept

Serum microRNAs identified as potential biomarkers in primary sclerosing cholangitis

Eisai submits NDS for Belviq in Canada

EMD Serono creates immune-oncology research and early development platform

Phase II study of enzalutamide in breast cancer enrolls first patient

Clinical trial of plasminogen eye drops in ligneous conjunctivitis begins

Kyowa Hakko Kirin files for approval of pegfilgrastim in Japan

Application filed in Japan to expand Regpara indication

Novel lipogenesis inhibitors patented by Pierre Fabre Medicament

Researchers at Janssen Pharmaceutica design new stearoyl-CoA desaturase inhibitors

Leo Pharma synthesizes new phosphate transporter inhibitors

New beta-secretase inhibitors disclosed by Janssen Pharmaceutica

Portola to test factor Xa inhibitor antidote with edoxaban

FDA approves Baxter's Rixubis for routine prophylaxis of hemophilia B

Lyxumia approved in Japan for type 2 diabetes

Irtra combination tablets approved for hypertension in Japan

Japan approves Perjeta for HER2-positive inoperable or recurrent breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...